Y
Yong Chan Ahn
Researcher at Samsung Medical Center
Publications - 290
Citations - 8211
Yong Chan Ahn is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Radiation therapy & Lung cancer. The author has an hindex of 41, co-authored 262 publications receiving 7009 citations. Previous affiliations of Yong Chan Ahn include Myongji University & Sungkyunkwan University.
Papers
More filters
Journal ArticleDOI
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee,Do Hoon Lim,Sung Kim,Se Hoon Park,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Min Gew Choi,Tae Sung Sohn,Jae Hyung Noh,Jae Moon Bae,Yong Chan Ahn,Insuk Sohn,Sin-Ho Jung,Sin-Ho Jung,Cheol Keun Park,Kyoung-Mee Kim,Won Ki Kang +17 more
TL;DR: The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in Gastric cancer and a subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.
Journal ArticleDOI
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
A. Ashworth,Suresh Senan,David A. Palma,Marc Riquet,Yong Chan Ahn,Umberto Ricardi,Maria Teresa Congedo,Daniel R. Gomez,Gavin M. Wright,Giulio Melloni,Michael T. Milano,Claudio V. Sole,Tommaso De Pas,Dennis L. Carter,Andrew Warner,George Rodrigues +15 more
TL;DR: Significant OS differences were observed in oligometastatic patients stratified according to type of metastatic presentation, and N status, and this risk classification scheme is proposed to be used in guiding selection of patients for clinical trials of ablative treatment.
Journal ArticleDOI
Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study
Seok Jin Kim,Ki-Hyun Kim,Byung Soo Kim,Chul Yong Kim,Cheolwon Suh,Jooryung Huh,Sang-wook Lee,Jin Seok Kim,Jaeho Cho,Gyeong Won Lee,Ki Mun Kang,Hyeon Seok Eom,Hong Ryull Pyo,Yong Chan Ahn,Young Hyeh Ko,Won Kim +15 more
TL;DR: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT, a phase II trial of concurrent chemoradiotherapy followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone.
Journal ArticleDOI
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
Sarah Park,Jeeyun Lee,Young Hyeh Ko,Arum Han,Hyun Jung Jun,Sang Chul Lee,In Gyu Hwang,Yeon Hee Park,Jin Seok Ahn,Chul Won Jung,Ki-Hyun Kim,Yong Chan Ahn,Won Ki Kang,Keunchil Park,Won Seog Kim +14 more
TL;DR: Takeaway is that DLBCL patients with EBER in situ hybridization+ pursued more rapidly deteriorating clinical course with poorer treatment response, survival, and progression-free survival.
Journal ArticleDOI
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn,Yong Chan Ahn,Joo Hang Kim,Chang Geol Lee,Eun Kyung Cho,Kyu Chan Lee,Ming Chen,Dong Wan Kim,Hoon Kyo Kim,Young Joo Min,Jin Hyoung Kang,Jin Hyuck Choi,Sang We Kim,Guangying Zhu,Yi-Long Wu,Sung Rok Kim,Kyung Hee Lee,Hong Suk Song,Yoon-La Choi,Jong Mu Sun,Sin-Ho Jung,Myung-Ju Ahn,Keunchil Park +22 more
TL;DR: CC with DP after CCRT with weekly DP in LA-NSCLC failed to further prolong PFS, and C CRT alone should remain the standard of care.